• Mediwell Enterprise Pte. Ltd (Mediwell) appointed as distribution partner for Singapore.
• Singapore has a fast-growing market for in-vitro diagnostic (IVD) tests.
Melbourne, Australia, 04 Feb 2019: Sienna Cancer Diagnostics Ltd, (ASX:SDX) (“Sienna” or “The Company”), a medical technology company developing and commercialising innovative cancer- related tests, continues expansion into Asia with the signing of distribution partner for Singapore.
Sienna is pleased to announce it has appointed Mediwell as the Company’s non-exclusive distribution partner for Singapore. The distribution agreement adds to the presence Sienna has in the Asian market following the appointment of an exclusive distributor for mainland China in 2018, followed by South Korea in January this year. The agreement allows Mediwell the right to sell Sienna’s in-vitro diagnostic hTERT test to pathology labs and hospitals where it will be used as an adjunct to urine cytology, assisting pathologists and urologists in the diagnosis of bladder cancer. Singapore has a population of approximately 5.8 million people and is one of the fastest growing consumers of IVD products globally.
For further information please download PDF attached:
Download this document
